SCH-217,443

SCH-217,443

SCH-217,443 is a chemical compound that has been studied for its potential pharmacological effects. It is primarily known for its role as a selective antagonist of the serotonin 5-HT6 receptor, which is a target of interest in the development of treatments for cognitive disorders and other neurological conditions.

Chemical Structure and Properties

SCH-217,443 is a synthetic compound with a complex molecular structure. The chemical formula for SCH-217,443 is C21H26N2O2, and it has a molecular weight of 338.45 g/mol. The compound is characterized by its specific binding affinity to the 5-HT6 receptor, which is a G protein-coupled receptor predominantly found in the central nervous system.

Pharmacological Action

The primary action of SCH-217,443 is as a selective antagonist of the 5-HT6 receptor. This receptor is involved in the modulation of neurotransmitter release, including acetylcholine, dopamine, and glutamate, which are critical for cognitive processes such as learning and memory. By blocking the 5-HT6 receptor, SCH-217,443 has been shown to enhance cognitive function in preclinical studies.

Research and Development

Research into SCH-217,443 has focused on its potential therapeutic applications in treating cognitive impairments associated with conditions such as Alzheimer's disease and schizophrenia. Preclinical studies have demonstrated that SCH-217,443 can improve performance in animal models of memory and learning deficits.

Clinical Trials

As of the latest updates, SCH-217,443 has undergone various phases of clinical trials to assess its safety, tolerability, and efficacy in humans. These trials aim to determine the potential of SCH-217,443 as a treatment for cognitive disorders. However, detailed results and the current status of these trials should be consulted from the latest scientific literature and clinical trial registries.

Potential Side Effects

Like many pharmacological agents, SCH-217,443 may have side effects. Commonly reported side effects in clinical trials include headache, nausea, and dizziness. The safety profile of SCH-217,443 continues to be evaluated in ongoing research.

Also see

• 5-HT6 receptor
• Cognitive enhancers
• Serotonin receptor antagonists
• Alzheimer's disease treatment

   This article is a  stub. You can help WikiMD by expanding it!

This article is a stub related to pharmacology. You can help WikiMD by expanding it!